Quick Takeaways
- Newpath Partners, L.P. filed SCHEDULE 13G/A for Prime Medicine, Inc. Common Stock, par value $0.00001 per share (PRME).
- Disclosed ownership: 4.7%.
- Date of event: 31 Dec 2024.
Newpath Partners, L.P. - 31 Dec 2024 SCHEDULE 13G/A Report for Prime Medicine, Inc. Common Stock, par value $0.00001 per share (PRME)
- Filing Manager
- Newpath Partners, L.P.
- Reporting Manager
- Newpath Partners, L.P.
- Symbol
- PRME
- Shares outstanding
- 129,908,064 shares
- Disclosed Ownership
- 6,105,679 shares
- Ownership
- 4.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 16:15:10 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Newpath Partners, L.P. disclosed 4.7% ownership in Prime Medicine, Inc. Common Stock, par value $0.00001 per share (PRME) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Newpath Partners, L.P. | 4.7% | 6,105,679 | 0 | 6,105,679 | By: Newpath Partners GP, L.P. By: /s/ Thomas Cahill | Thomas Cahill, Managing Member | |
| Newpath Partners GP, L.P. | 4.7% | 6,105,679 | 0 | 6,105,679 | By: Newpath Partners GP, LLC By: /s/ Thomas Cahill | Thomas Cahill, Managing Member | |
| Newpath Partners GP, LLC | 4.7% | 6,105,679 | 0 | 6,105,679 | /s/ Thomas Cahill | Thomas Cahill, Managing Member | |
| Thomas Cahill | 4.7% | 6,105,679 | 0 | 6,105,679 | /s/ Thomas Cahill | Thomas Cahill |